Aln-6222
Phase 1
Alnylam PharmaceuticalsAln-6222 is one of 46 therapeutic programs targeting Obesity. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
45
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
190 competitors in Obesity
#DrugCompanyPhaseTrials
1Maridebart Cafraglutide
AmgenPhase 3
NNC0487-0111
Novo NordiskPhase 3
Gemtesa
Sumitomo Pharma America, Inc.Phase 3
Zenagamtide
Novo NordiskPhase 3
Berobenatide
PfizerPhase 3
Ribupatide
KKailera
Phase 3
Elecoglipron
AstraZenecaPhase 3
PF-08653944
PfizerPhase 3
Survodutide
Boehringer IngelheimPhase 3
Avapro
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Aln-6222. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]
- Company